149 related articles for article (PubMed ID: 22747525)
1. Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer.
Mohammed ZM; Going JJ; McMillan DC; Orange C; Mallon E; Doughty JC; Edwards J
Histopathology; 2012 Oct; 61(4):675-84. PubMed ID: 22747525
[TBL] [Abstract][Full Text] [Related]
2. Comparison of visual and automated assessment of microvessel density and their impact on outcome in primary operable invasive ductal breast cancer.
Mohammed ZM; Orange C; McMillan DC; Mallon E; Doughty JC; Edwards J; Going JJ
Hum Pathol; 2013 Aug; 44(8):1688-95. PubMed ID: 23574778
[TBL] [Abstract][Full Text] [Related]
3. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays.
Laurinaviciene A; Dasevicius D; Ostapenko V; Jarmalaite S; Lazutka J; Laurinavicius A
Diagn Pathol; 2011 Sep; 6():87. PubMed ID: 21943197
[TBL] [Abstract][Full Text] [Related]
4. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques.
Ellis CM; Dyson MJ; Stephenson TJ; Maltby EL
J Clin Pathol; 2005 Jul; 58(7):710-4. PubMed ID: 15976337
[TBL] [Abstract][Full Text] [Related]
5. Computer Aided Semi-Automated Evaluation of HER2 Immunodetection--A Robust Solution for Supporting the Accuracy of Anti HER2 Therapy.
Micsik T; Kiszler G; Szabó D; Krecsák L; Hegedűs C; Tibor K; Molnár B
Pathol Oncol Res; 2015 Sep; 21(4):1005-11. PubMed ID: 25788005
[TBL] [Abstract][Full Text] [Related]
6. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
7. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
[TBL] [Abstract][Full Text] [Related]
8. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer outcomes by steroid hormone receptor status assessed visually and by computer image analysis.
Mohammed ZM; Edwards J; Orange C; Mallon E; Doughty JC; McMillan DC; Going JJ
Histopathology; 2012 Aug; 61(2):283-92. PubMed ID: 22571413
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis.
Hanley KZ; Siddiqui MT; Lawson D; Cohen C; Nassar A
Diagn Cytopathol; 2009 Apr; 37(4):251-7. PubMed ID: 19217031
[TBL] [Abstract][Full Text] [Related]
11. An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.
O'Grady A; Allen D; Happerfield L; Johnson N; Provenzano E; Pinder SE; Tee L; Gu M; Kay EW
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):489-93. PubMed ID: 20661132
[TBL] [Abstract][Full Text] [Related]
12. [Availability of fine needle aspirates for the assessment of HER2 gene amplification in invasive breast cancer patients].
Lee JW; Noh WC; Kim MS; Kim HA; Chang YH; Hong YJ; Hong SI; Lee JK
Korean J Lab Med; 2008 Oct; 28(5):392-9. PubMed ID: 18971621
[TBL] [Abstract][Full Text] [Related]
13. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
[TBL] [Abstract][Full Text] [Related]
14. Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study.
van der Logt EM; Kuperus DA; van Setten JW; van den Heuvel MC; Boers JE; Schuuring E; Kibbelaar RE
PLoS One; 2015; 10(4):e0123201. PubMed ID: 25844540
[TBL] [Abstract][Full Text] [Related]
15. Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation.
Atkinson R; Mollerup J; Laenkholm AV; Verardo M; Hawes D; Commins D; Engvad B; Correa A; Ehlers CC; Nielsen KV
Arch Pathol Lab Med; 2011 Aug; 135(8):1010-6. PubMed ID: 21809992
[TBL] [Abstract][Full Text] [Related]
16. HER2/neu revisited: quality and interpretive issues.
Ahmed SS; Iqbal J; Thike AA; Lim AS; Lim TH; Tien SL; Tan PH
J Clin Pathol; 2011 Feb; 64(2):120-4. PubMed ID: 21131629
[TBL] [Abstract][Full Text] [Related]
17. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
18. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
19. Digital image analysis of membrane connectivity is a robust measure of HER2 immunostains.
Brügmann A; Eld M; Lelkaitis G; Nielsen S; Grunkin M; Hansen JD; Foged NT; Vyberg M
Breast Cancer Res Treat; 2012 Feb; 132(1):41-9. PubMed ID: 21512768
[TBL] [Abstract][Full Text] [Related]
20. Dual HER2 gene protein assay: focused study of breast cancers with 2+ immunohistochemical expression.
Li Z; Dabbs DJ; Cooper KL; Bhargava R
Am J Clin Pathol; 2015 Mar; 143(3):451-8. PubMed ID: 25696805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
